Clinical Trial Update: Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency [Phase 3]

View source ↗

Summary

This clinical trial update describes an ongoing Phase 3 study evaluating the long-term safety of alpha1-proteinase inhibitor in individuals with alpha-1 antitry…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency
• Pulmonary Emphysema

Drugs mentioned

• Glassia (alpha-1 proteinase inhibitor)

Snippet

Sponsor: Grifols Therapeutics LLC | Conditions: Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency | Phase 3 | Status: ENROLLING_BY_INVITATION